Volume 95 Issue 25 | p. 8 | News of The Week
Issue Date: June 19, 2017 | Web Date: June 14, 2017

FDA takes aim at opioid epidemic

Agency wants to pull opioid from market because it says the drug’s benefits don’t outweigh its risks
Department: Science & Technology
Keywords: molecule of the moment, drug safety, opioid epidemic, oxymorphone, FDA, drug formulation

The U.S. Food & Drug Administration has requested that Endo Pharmaceuticals remove its painkiller Opana ER from the market. Opana ER’s active ingredient, oxymorphone, is an opioid similar to morphine but with an added hydroxyl group that makes it 10 times as potent. The agency says this is the first time it has taken steps to halt sales of an opioid over concerns of public abuse. . . .

To view the rest of this content, please log in with your ACS ID.



 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society